{"transactions":[{"id":740091,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T21:56:36.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":80000,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073614","document":"tm2617880-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926073614/tm2617880-7_4seq1.xml","form_type":"4"}},{"id":770128,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:33:09.000Z","date":"2026-05-19","kind":"purchase","planned":false,"acquired":true,"shares":56818,"price":0.88,"value":49999.84,"ownership":{"direct":true},"balance_after":148025,"source":{"system":"sec-edgar","filing":"0001654316-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000165431626000002/ownership.xml","form_type":"4"}},{"id":1109873,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T20:30:36.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000107","document":"wk-form4_1750105821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000107/wk-form4_1750105821.xml","form_type":"4"}},{"id":1175701,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-08T20:15:54.000Z","date":"2025-04-08","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":1.32,"value":66000.0,"ownership":{"direct":true},"balance_after":91207,"source":{"system":"sec-edgar","filing":"0001818382-25-000046","document":"wk-form4_1744143346.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000046/wk-form4_1744143346.xml","form_type":"4"}},{"id":1324485,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-20T16:30:07.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":7672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 17, 2024, the Reporting Person filed a Form 4 which, due to an administrative error, incorrectly reported that the Reporting person had been awarded 6,889 shares of restricted stock pursuant to the Company's non-employee director compensation policy. This amendment to Form 4 is being filed to reflect the correct amount of shares awarded pursuant to the policy."}],"balance_after":32671,"source":{"system":"sec-edgar","filing":"0000950170-24-139088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000095017024139088/ownership.xml","form_type":"4/A","original_submission_date":"2024-06-17"}},{"id":1409837,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-09-11T21:53:12.000Z","date":"2024-09-10","kind":"exercise","planned":false,"acquired":false,"shares":2479,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6021,"derivative":{"exercise_price":3.35,"exercise_date":"2024-08-15","expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":2479},"source":{"system":"sec-edgar","filing":"0001818382-24-000186","document":"wk-form4_1726091586.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000186/wk-form4_1726091586.xml","form_type":"4"}},{"id":1409836,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-09-11T21:53:12.000Z","date":"2024-09-10","kind":"exercise","planned":false,"acquired":false,"shares":4521,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3979,"derivative":{"exercise_price":4.34,"exercise_date":"2024-08-09","expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":4521},"source":{"system":"sec-edgar","filing":"0001818382-24-000186","document":"wk-form4_1726091586.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000186/wk-form4_1726091586.xml","form_type":"4"}},{"id":1409835,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T21:53:12.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":1548,"price":5.39,"value":8343.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.38 to $5.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41207,"source":{"system":"sec-edgar","filing":"0001818382-24-000186","document":"wk-form4_1726091586.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000186/wk-form4_1726091586.xml","form_type":"4"}},{"id":1409834,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T21:53:12.000Z","date":"2024-09-10","kind":"exercise","planned":false,"acquired":true,"shares":2479,"price":3.35,"value":8304.65,"ownership":{"direct":true},"balance_after":42755,"source":{"system":"sec-edgar","filing":"0001818382-24-000186","document":"wk-form4_1726091586.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000186/wk-form4_1726091586.xml","form_type":"4"}},{"id":1409833,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T21:53:12.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":3634,"price":5.41,"value":19659.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.411 to $5.42. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40276,"source":{"system":"sec-edgar","filing":"0001818382-24-000186","document":"wk-form4_1726091586.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000186/wk-form4_1726091586.xml","form_type":"4"}},{"id":1409832,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T21:53:12.000Z","date":"2024-09-10","kind":"exercise","planned":false,"acquired":true,"shares":4521,"price":4.34,"value":19621.14,"ownership":{"direct":true},"balance_after":43910,"source":{"system":"sec-edgar","filing":"0001818382-24-000186","document":"wk-form4_1726091586.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000186/wk-form4_1726091586.xml","form_type":"4"}},{"id":1477454,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-06-17T20:15:53.000Z","date":"2024-06-14","kind":"exercise","planned":false,"acquired":false,"shares":39389,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.56,"exercise_date":"2018-09-01","expiration_date":"2025-09-01","underlying":"Common Stock","underlying_shares":39389},"source":{"system":"sec-edgar","filing":"0001818382-24-000143","document":"wk-form4_1718655345.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000143/wk-form4_1718655345.xml","form_type":"4"}},{"id":1477453,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-06-17T20:15:53.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028."}],"balance_after":50000,"derivative":{"exercise_price":7.2,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001818382-24-000143","document":"wk-form4_1718655345.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000143/wk-form4_1718655345.xml","form_type":"4"}},{"id":1477452,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-17T20:15:53.000Z","date":"2024-06-14","kind":"exercise","planned":false,"acquired":true,"shares":39389,"price":2.56,"value":100835.84,"ownership":{"direct":true},"balance_after":39389,"source":{"system":"sec-edgar","filing":"0001818382-24-000143","document":"wk-form4_1718655345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000143/wk-form4_1718655345.xml","form_type":"4"}},{"id":1477714,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-17T17:30:13.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy."}],"balance_after":31888,"source":{"system":"sec-edgar","filing":"0000950170-24-074414","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000095017024074414/ownership.xml","form_type":"4"}},{"id":1852546,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2023-06-16T20:11:59.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 15, 2024, after which 1/48 of the option will become exercisable on the 15th of each month through June 15, 2027."}],"balance_after":8500,"derivative":{"exercise_price":3.35,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001818382-23-000091","document":"wf-form4_168694629960516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000091/wf-form4_168694629960516.xml","form_type":"4"}},{"id":1859264,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T16:19:48.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":3599,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy."}],"balance_after":24999,"source":{"system":"sec-edgar","filing":"0001209191-23-036287","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919123036287/doc4.xml","form_type":"4"}},{"id":2234305,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-06-13T20:23:26.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 9, 2023, after which 1/48 of the option will become exercisable on the 9th of each month through June 9, 2026."}],"balance_after":8500,"derivative":{"exercise_price":4.34,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001818382-22-000096","document":"wf-form4_165515179132864.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838222000096/wf-form4_165515179132864.xml","form_type":"4"}},{"id":2234513,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-13T17:15:14.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":7523,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy."}],"balance_after":21400,"source":{"system":"sec-edgar","filing":"0001209191-22-036391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919122036391/doc4.xml","form_type":"4"}},{"id":2541759,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2021-10-15T19:35:16.000Z","date":"2021-10-13","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025."}],"balance_after":8500,"derivative":{"exercise_price":10.03,"expiration_date":"2031-10-13","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001104659-21-126708","document":"tm2130120-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465921126708/tm2130120-8_4seq1.xml","form_type":"4"}},{"id":2588494,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T20:11:14.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":17068,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 26, 2021, Alpha Healthcare Acquisition Corp. (\"AHAC\") consummated a business combination (the \"Business\nCombination\") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation (\"Hunter Merger Sub\") and Humacyte, Inc.,\na Delaware corporation (\"Legacy Humacyte\"), AHAC changed its name to \"Humacyte, Inc.\" and Hunter Merger Sub merged with\nand into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock\noption to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options are fully vested and exercisable."}],"balance_after":17068,"derivative":{"exercise_price":6.54,"expiration_date":"2028-04-12","underlying":"Common Stock","underlying_shares":17068},"source":{"system":"sec-edgar","filing":"0001104659-21-110533","document":"tm2125954-20_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465921110533/tm2125954-20_4seq1.xml","form_type":"4"}},{"id":2588493,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T20:11:14.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":39389,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 26, 2021, Alpha Healthcare Acquisition Corp. (\"AHAC\") consummated a business combination (the \"Business\nCombination\") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation (\"Hunter Merger Sub\") and Humacyte, Inc.,\na Delaware corporation (\"Legacy Humacyte\"), AHAC changed its name to \"Humacyte, Inc.\" and Hunter Merger Sub merged with\nand into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock\noption to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options are fully vested and exercisable."}],"balance_after":39389,"derivative":{"exercise_price":2.56,"expiration_date":"2025-09-01","underlying":"Common Stock","underlying_shares":39389},"source":{"system":"sec-edgar","filing":"0001104659-21-110533","document":"tm2125954-20_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465921110533/tm2125954-20_4seq1.xml","form_type":"4"}},{"id":2645469,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T16:12:32.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":2699,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy."}],"balance_after":13877,"source":{"system":"sec-edgar","filing":"0001209191-21-044932","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919121044932/doc4.xml","form_type":"4"}},{"id":3000886,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-23T16:46:57.000Z","date":"2020-10-22","kind":"grant","acquired":true,"shares":420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy."}],"balance_after":11178,"source":{"system":"sec-edgar","filing":"0001209191-20-055690","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919120055690/doc4.xml","form_type":"4"}},{"id":3028488,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-17T16:12:00.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":21603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest and become exercisable on the earlier of (a) September 15, 2021, and (b) the date that is one day prior to the Issuer's 2021 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date."}],"balance_after":21603,"derivative":{"exercise_price":21.47,"expiration_date":"2030-09-14","underlying":"Common Shares","underlying_shares":21603},"source":{"system":"sec-edgar","filing":"0001209191-20-050873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000120919120050873/doc4.xml","form_type":"4"}},{"id":3076359,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-24T16:34:15.000Z","date":"2020-07-23","kind":"grant","acquired":true,"shares":2558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy."}],"balance_after":10758,"source":{"system":"sec-edgar","filing":"0001209191-20-043606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919120043606/doc4.xml","form_type":"4"}},{"id":3253012,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-02-24T19:31:44.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-20-001615","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218020001615/primarydocument.xml","form_type":"4"}},{"id":3253011,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:31:44.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.38,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001615","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218020001615/primarydocument.xml","form_type":"4"}},{"id":3253010,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:31:44.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.95,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001615","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218020001615/primarydocument.xml","form_type":"4"}},{"id":3253009,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:31:44.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.01,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001615","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218020001615/primarydocument.xml","form_type":"4"}},{"id":3253008,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:31:44.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.82,"expiration_date":"2026-06-20","underlying":"Common Stock","underlying_shares":6896},"source":{"system":"sec-edgar","filing":"0001562180-20-001615","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218020001615/primarydocument.xml","form_type":"4"}},{"id":3253007,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:31:44.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":20689,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":23.34,"expiration_date":"2025-06-10","underlying":"Common Stock","underlying_shares":20689},"source":{"system":"sec-edgar","filing":"0001562180-20-001615","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218020001615/primarydocument.xml","form_type":"4"}},{"id":3253006,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-24T19:31:44.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"price":18.75,"value":112500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-20-001615","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218020001615/primarydocument.xml","form_type":"4"}},{"id":3428223,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-27T16:48:41.000Z","date":"2019-08-23","kind":"grant","acquired":true,"shares":58608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 23, 2020, and (b) the date that is one day prior to the Issuer's 2020 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date."}],"balance_after":58608,"derivative":{"exercise_price":7.65,"expiration_date":"2029-08-22","underlying":"Common Shares","underlying_shares":58608},"source":{"system":"sec-edgar","filing":"0001209191-19-047533","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000120919119047533/doc4.xml","form_type":"4"}},{"id":3455319,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-26T17:01:11.000Z","date":"2019-07-25","kind":"grant","acquired":true,"shares":3981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy."}],"balance_after":8200,"source":{"system":"sec-edgar","filing":"0001209191-19-043379","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119043379/doc4.xml","form_type":"4"}},{"id":3489640,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T17:16:06.000Z","date":"2019-06-12","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU, which was granted on June 12, 2018, fully vested on June 12, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-19-003529","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218019003529/primarydocument.xml","form_type":"4"}},{"id":3489639,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T17:16:06.000Z","date":"2019-06-12","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001562180-19-003529","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218019003529/primarydocument.xml","form_type":"4"}},{"id":3489638,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-06-14T16:20:46.000Z","date":"2019-06-12","kind":"purchase","acquired":true,"shares":4500,"price":8.96,"value":40320.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-19-037137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000120919119037137/doc4.xml","form_type":"4"}},{"id":3489637,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-06-14T16:20:46.000Z","date":"2019-06-12","kind":"purchase","acquired":true,"shares":300,"price":8.92,"value":2676.0,"ownership":{"direct":true},"balance_after":500,"source":{"system":"sec-edgar","filing":"0001209191-19-037137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000120919119037137/doc4.xml","form_type":"4"}},{"id":3489636,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-06-14T16:20:46.000Z","date":"2019-06-12","kind":"purchase","acquired":true,"shares":100,"price":8.93,"value":893.0,"ownership":{"direct":true},"balance_after":200,"source":{"system":"sec-edgar","filing":"0001209191-19-037137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000120919119037137/doc4.xml","form_type":"4"}},{"id":3489635,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-06-14T16:20:46.000Z","date":"2019-06-12","kind":"purchase","acquired":true,"shares":100,"price":8.95,"value":895.0,"ownership":{"direct":true},"balance_after":100,"source":{"system":"sec-edgar","filing":"0001209191-19-037137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000120919119037137/doc4.xml","form_type":"4"}},{"id":3498947,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2019-06-06T20:15:55.000Z","date":"2019-06-04","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU will vest 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-19-003407","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218019003407/primarydocument.xml","form_type":"4"}},{"id":3498946,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-06-06T20:15:55.000Z","date":"2019-06-04","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest and become exercisable as to 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":9.38,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-19-003407","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218019003407/primarydocument.xml","form_type":"4"}},{"id":3608967,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-06T16:28:49.000Z","date":"2019-03-04","kind":"grant","acquired":true,"shares":4219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy and vest in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":4219,"source":{"system":"sec-edgar","filing":"0001209191-19-017350","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119017350/doc4.xml","form_type":"4"}},{"id":3827413,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-09-04T16:48:49.000Z","date":"2018-08-31","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 31, 2019, and (b) the date that is one day prior to the Issuer's 2019 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date."}],"balance_after":22500,"derivative":{"exercise_price":24.25,"expiration_date":"2028-08-30","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-18-049225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000120919118049225/doc4.xml","form_type":"4"}},{"id":3893997,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2018-06-14T17:45:54.000Z","date":"2018-06-13","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSU, which was granted on June 13, 2017, fully vested on June 13, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-18-003005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218018003005/primarydocument.xml","form_type":"4"}},{"id":3893996,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2018-06-14T17:45:54.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSU will vest 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-18-003005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218018003005/primarydocument.xml","form_type":"4"}},{"id":3893995,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-06-14T17:45:54.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest and become exercisable as to 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":9.95,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-18-003005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218018003005/primarydocument.xml","form_type":"4"}},{"id":3893994,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-14T17:45:54.000Z","date":"2018-06-13","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired upon vesting of RSU granted on June 13, 2017."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001562180-18-003005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218018003005/primarydocument.xml","form_type":"4"}},{"id":4182463,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-20T16:47:50.000Z","date":"2017-08-18","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 18, 2018, and (b) the date that is one day prior to the Issuer's 2018 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date."}],"balance_after":22500,"derivative":{"exercise_price":13.14,"expiration_date":"2027-08-17","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-17-057648","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000120919117057648/doc4.xml","form_type":"4"}},{"id":4280885,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2017-06-15T19:19:04.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU will vest 100% of the shares on June 13, 2018, subject to the continuing service of the Reporting Person on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-17-002281","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218017002281/primarydocument.xml","form_type":"4"}},{"id":4280884,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-06-15T19:19:04.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest and become exercisable as to 100% of the shares on June 13, 2018, subject to the continuing service of the Reporting Person on such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":28.01,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-17-002281","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000156218017002281/primarydocument.xml","form_type":"4"}},{"id":4315966,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-17T17:17:56.000Z","date":"2017-05-15","kind":"grant","acquired":true,"shares":11154,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares underlying the option vest and become exercisable on May 15, 2018; the balance of the shares vest and become exercisable in a series of eight (8) successive equal quarterly installments measured from May 15, 2018, subject to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":11154,"derivative":{"exercise_price":12.68,"expiration_date":"2027-05-14","underlying":"Common Shares","underlying_shares":11154},"source":{"system":"sec-edgar","filing":"0001209191-17-033258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654316/000120919117033258/doc4.xml","form_type":"4"}}]}